Session » Sjögren's Syndrome I: Basic Insights

Date: Sunday, November 8, 2015

Time: 4:30PM-6:00PM

Meeting: 2015 ACR/ARHP Annual Meeting

4:30PM-6:00PM: Abstract Number: 1054

A Potential Role of Type III Interferon in the Glandular Involvement of Sjögren’s Syndrome

4:30PM-6:00PM: Abstract Number: 1056

Aquaporin Gene Therapy Corrects Bone Morphogenetic Protein 6 Associated Exocrine Gland Dysfunction in Mouse Model of Sjögren’s Syndrome

4:30PM-6:00PM: Abstract Number: 1055

Expansions of Salivary Gland CD4+ T Cells from Sjögren’s Syndrome Patients: Single-Cell Repertoire Analysis and Correlation with Clinical Measures of Disease

4:30PM-6:00PM: Abstract Number: 1052

Identification of Novel Sjogren’s Syndrome Risk Loci in the Regions of TNFAIP3 and PRDM1

4:30PM-6:00PM: Abstract Number: 1053

Phosphatidylinositol-3-Kinase Delta Pathway a Novel Therapeutic Target for Sjogren’s Syndrome

4:30PM-6:00PM: Abstract Number: 1051

Serum Calprotectin As Biomarker of Carotid Atherosclerosis in Patients with Primary Sjögren’s Syndrome

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].